Stay updated with breaking news from Biocon Biologic. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Pharmaceutical giants Biocon Biologics has successfully completed the transition of its acquired biosimilars business in 120 countries across advanced and emerging markets, a year ahead of schedule, an official release stated on Monday. Over 10
Biocon Biologics, a unique, fully integrated, global biosimilars company with a rich portfolio of insulins and monoclonal antibodies, has successfully concluded the integration of the acquired Viatris biosimilars business with the transition of 10+ Emerging Markets and Japan, Australia and New Zealand in the final phase.
Earlier in 2023, over 70 Emerging Markets were integrated in July, the North American business transitioned in September and the European business in November, , Biocon Biologics
JB Chemicals & Pharmaceuticals (JB Pharma), controlled by US private equity firm KKR, is evaluating assets for acquisitions to strengthen its market share in the domestic branded formulation business. CEO Nikhil Chopra said the assets should be at the right valuation and have synergy with the existing business, with a payback period of seven to eight years.
Eris Lifesciences Ltd, a Mumbai-listed pharmaceutical company backed by private equity firm ChrysCapital and Kuwait Investment Authority, has agreed to purchase Biocon Biologics Ltd’s dermatology and ......